Summary
Amgen Inc. (AMGN) filed an 8-K report on March 1, 2002, disclosing a significant financing transaction. On March 1, 2002, the company successfully issued $3.95 billion in aggregate principal face amount of 30-year zero-coupon senior notes, which are convertible into Amgen common stock. The gross proceeds generated from this offering amounted to approximately $2.8 billion. These substantial funds are earmarked for strategic corporate initiatives. A significant portion, approximately $650 million, will be used to repurchase the company's common stock concurrently with the note issuance. The remaining proceeds are allocated for general corporate purposes, including potential acquisitions, further share repurchases, capital expenditures, and working capital needs. This move signals Amgen's proactive approach to capital management and its intention to enhance shareholder value through strategic investments and capital allocation.
Key Highlights
- 1Amgen Inc. issued $3.95 billion in 30-year zero-coupon senior convertible notes on March 1, 2002.
- 2Gross proceeds from the note issuance were approximately $2.8 billion.
- 3The notes are convertible into shares of Amgen common stock.
- 4Proceeds will fund a $650 million share repurchase program initiated concurrently with the note issuance.
- 5Remaining funds are designated for general corporate purposes, including acquisitions, further share repurchases, capital expenditures, and working capital.
- 6The filing indicates a proactive capital management strategy by Amgen.
- 7The transaction was structured with involvement from financial institutions like Merrill Lynch.